Complement System

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.

Cyclosporin A is a naturally occurring cyclic polypeptide that is the active metabolite of a fungus. Cyclosporin A is an immunosuppressant that binds to procyclins and inhibits calcineurin (IC50=7 nM).

Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist and IL receptor modulator with anti-inflammatory and immunosuppressive properties that induces autophagy and inhibits LPS-induced inflammatory responses in macrophages.

JR14a (5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride) is a potent antagonist of human complement C3a receptor.

Lipoteichoic acid, a polymer of the cell wall of gram-positive bacteria, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition via the IGF-1 pathway.

SB290157 trifluoroacetate is a potent and selective antagonist of the C3a receptor, with an IC50 of 200 nM.

Compstatin is a cyclic peptide consisting of 13 amino acid residues and is a potent inhibitor of complement system C3. Compstatin is species-specific and has inhibitory effects only on the complement system of primates. Studies have shown that it can bind to baboon C3 and is resistant to proteolytic cleavage in baboon blood. Its IC50 values for the classical pathway and alternative pathway are 63 μM and 12 μM, respectively.

EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 μM and an IC50 value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.EG01377 exhibits anti-angiogenic, antimigratory and antitumor activities.

Complement factor D-IN-2 is an inhibitor that reduces the excessive activation of Complement factor D.

Avacopan (CCX168) is a C5aR antagonist (IC50=0.1 nM) with selective and oral activity. Avacopan blocks the action of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a mouse model of AAV. Avacopan can be used to treat anti-neutrophil cytoplasmic antibody (ANCA)-related vasculitis.

Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemolysis.

C3a Receptor Agonist (C3a receptor agonist 1) binds the G protein-coupled C3a receptors (C3aRs) in the immune system complement pathway. Activation of C3aR prevents neutrophils from being mobilized in a model of intestinal ischemia-reperfusion injury. C3aRs are expressed on neural progenitor cells and immature neurons in adult mice. C3a stimulates differentiation of neural progenitor cells in vitro.

Factor B-IN-5 is a complement factor B inhibitor, which can be used to study immune-related diseases.

BCX 1470 hydrochloride is a potent serine protease inhibitor with anti-inflammatory activity that inhibits the ester hydrolysis and haemolytic activity of factor D and C1s, and can be used to study oedema.

Danicopan (ACH-4471) (ACH-4471) is a selective, orally active small molecule factor D inhibitor with high binding affinity to human factor D, with a Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits the activity of the complement replacement pathway (APC) and may block the complement replacement pathway in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Pozelimab (REGN 3918) is a humanized antibody targeting component 5 (C5), used for research on Pozelimab disease.

PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

Tesidolumab (LFG316) is a fully human IgG1 λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cutting of C5 and preventing the subsequent formation of membrane attack complex, which can be used to study extravascular hemolysis.

LEP(116-130)(mouse) is a synthetic leptin peptide fragment.

PMX 205 acetate is an antagonist of complement C5a receptor (C5aR; CD88).

W-54011 is a potent non-peptide C5a receptor antagonist. W-54011 inhibits the binding of 125I-labeled C5a to human neutrophils (Ki: 2.2 nM). W-54011 inhibits C5a-induced intracellular Ca2+ mobilization, chemotaxis, and generation of ROS in human neutrophi

CP-289 is a potent C5a receptor antagonist with IC50 of 1 μM.

Leukadherin-1 is an allosteric activator of CD11b CD18. Increasing CD11b CD18-dependent cell adhesion to fibrinogen, Decreasing leukocyte motility and transendothelial migration; reduces inflammation.

ADH-503 (GB1275) is an orally available, allosteric CD11b small molecule agonist that can lead to repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhancement of dendritic cell responses.

CP-447697, a lipophilic C5a receptor antagonist, exhibits an IC50 of 31 nM. It is utilized in inflammation research.

NDT 9513727 is a potent, selective, and competitive C5aR1 inverse agonist used in the study of inflammatory and immune disorders.

C3a 70-77 2TFA(63555-63-5(free base)) (Complement 3a (70-77)) is an octapeptide corresponding to the COOH terminus of C3a.

Compstatin control peptide acetate is a negative control of Compstatin. Compstatin is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.

3-Phenoxybenzaldehyde is a complement (classical pathway) inhibitor with IC50 of 1388μM.

TLQP 21 acetate is a potent agonist of G-protein-coupled receptor complement-3a receptor 1 (C3aR1). The EC50 values are 10.3 μM for mouse and 68.8 μM for human. TLQP 21 acetate is a VGF-derived peptide with endocrine and extraendocrine properties.

Lampalizumab (RG 7417) is a humanized monoclonal antibody targeting Complement Factor D in the complement pathway, used in age-related macular degeneration (AMD) and cardiovascular disease research.

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Avdoralimab (IPH 5401) is a humanized monoclonal antibody targeting Complement C5a receptor 1 (C5aR1), used in research on bullous pemphigoid and chronic urticaria.

Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.

(Z)-Leukadherin-1 (ADH-503 free base) is an allosteric agonist of CD11b.

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

POT-4 acetate inhibits Complement C3 activation. POT-4 acetate can be used for studies about age-related macular degeneration.

C3a (70-77) is an octapeptide that corresponds to the COOH terminus of C3a.

C5a Anaphylatoxin (human) is a pro-inflammatory peptide that acts as a leukocyte chemoattractant and is used in research on inflammation and immune responses, including allergic asthma [1] [2].

Zilucoplan(PEG2) is a derivative of Zilucoplan where the linker component has been substituted with PEG2 instead of PEG24. This compound acts as an effective inhibitor of complement component 5 (C5).

C1qProtein (Mouse) is a subunit of the complement system. It recognizes a variety of ligands and plays roles in maintaining immune system balance, promoting tissue repair, and defending against pathogens.

Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent inhibitor of complement component 5 (C5) with applications in studying immune-mediated necrotising myopathy (IMNM) [1] [2].

C5aR2 agonist P32 acetate (Ac-RHYPYWR-OH), a selective agonist for C5aR2, has been shown to induce various immunomodulatory activities both in vitro and in vivo. It modulates cell signaling via the downregulation of C5aR1-mediated pathways and can also function independently of C5aR1.

4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a C3a receptor (C3a C3aR) axis and C5a C5a receptor 1 (C5a C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1 Th2 and regulatory T (Treg) Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR)) inhibitor κBα nuclear factor κB (TLR7 IκBα NF-κB) pathway.

Greziprubart is a humanized IgG1κ monoclonal antibody that targets C5a, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.